LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

New Harbor Capital and Origami Capital Recapitalize LGM Pharma

October 1, 2024

Pharmaceuticals

New Harbor Capital completed a single-asset continuation recapitalization of LGM Pharma in partnership with Origami Capital Partners to provide growth capital and facilitate liquidity for existing investors. LGM Pharma is a CDMO and API sourcing/distribution platform with manufacturing and analytical capabilities serving pharmaceutical, biotechnology and compounding pharmacy customers across multiple U.S. facilities.

Astorg Acquires Pharmaceutical CDMO CordenPharma from ICIG

May 2, 2022

Pharmaceuticals

Astorg has signed a binding agreement to acquire CordenPharma, a global contract development and manufacturing organization (CDMO) focused on APIs, excipients and drug products, from International Chemical Investors Group (ICIG). CordenPharma employs over 2,600 people across 11 manufacturing sites and an R&D laboratory in Europe and the US; the founders will reinvest alongside Astorg. The transaction is subject to customary regulatory approvals and terms were not disclosed.

Noramco Acquires Cambrex Drug Product Business Unit (Halo Pharmaceuticals)

November 2, 2023

Pharmaceuticals

Noramco has completed the acquisition of the Cambrex Drug Product Business Unit (previously Halo Pharmaceuticals), adding drug product formulation development, clinical and commercial manufacturing, and packaging capabilities from sites in Mirabel, Québec and Whippany, New Jersey. The purchase expands Noramco's service offering beyond APIs, brings nearly 400 employees into the Noramco group, and represents Cambrex's strategic divestiture to focus on its drug substance and analytical testing businesses.

Signet, Bionpharma and GMS Form Pharma Nobis to Acquire Fagron's U.S. Contract Manufacturing Business

February 4, 2022

Pharmaceuticals

An investor consortium led by Signet Healthcare Partners with Bionpharma, Inc. and GMS Capital Partners formed Pharma Nobis, LLC to acquire Fagron's U.S. contract manufacturing business and manufacturing facility in Texarkana, Texas. Fagron will retain a 20% interest in the new company; Todd Daviau was named CEO and the investors said they will seek to grow the contract manufacturing and private-label capabilities for consumer healthcare and retail customers.

Zydus Lifesciences Acquires Agenus' U.S. Biologics Manufacturing Facilities and Launches Zylidac Bio LLC

January 16, 2026

Biotechnology

Zydus Lifesciences Limited has completed purchase agreements with Agenus Inc. to acquire Agenus' biologics manufacturing facilities and operations in Emeryville and Berkeley, California, and has established a U.S. CDMO subsidiary, Zylidac Bio LLC, to operate the assets. The deal includes exclusive manufacturing arrangements for Agenus' Phase 3 immuno-oncology candidates (botensilimab and balstilimab), exclusive commercialization rights for those assets in India and Sri Lanka, and an equity investment in Agenus via Zynext Ventures; regulatory approvals including CFIUS clearance were secured.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.